PE20240885A1 - Sales agonistas de sstr4 - Google Patents
Sales agonistas de sstr4Info
- Publication number
- PE20240885A1 PE20240885A1 PE2024000415A PE2024000415A PE20240885A1 PE 20240885 A1 PE20240885 A1 PE 20240885A1 PE 2024000415 A PE2024000415 A PE 2024000415A PE 2024000415 A PE2024000415 A PE 2024000415A PE 20240885 A1 PE20240885 A1 PE 20240885A1
- Authority
- PE
- Peru
- Prior art keywords
- salts
- sstr4
- sstr4 agonist
- agonist salts
- 6alpha
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- 102100023801 Somatostatin receptor type 4 Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 title 1
- -1 3-methyl-2-pyridyl Chemical group 0.000 abstract 1
- 208000008035 Back Pain Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a sales especificas de (1S,5R)-(1alfa,5alfa,6alfa)-N-[1,1-dimetil-2-[(3-metil-2-piridil)oxi]etil]-3-azabiciclo[3.1.0]hexano-6-carboxamida como el compuesto de formula I o un hidrato de este, a composiciones farmaceuticas que comprenden dichas sales, a metodos de uso de dichas sales para tratar trastornos fisiologicos como el tratamiento del dolor de espalda cronico, neuropatico, entre otros, y a intermedios utiles en la sintesis de las sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243785P | 2021-09-14 | 2021-09-14 | |
| PCT/US2022/076401 WO2023044326A1 (en) | 2021-09-14 | 2022-09-14 | Sstr4 agonist salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240885A1 true PE20240885A1 (es) | 2024-04-24 |
Family
ID=83508479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000415A PE20240885A1 (es) | 2021-09-14 | 2022-09-14 | Sales agonistas de sstr4 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11834435B2 (es) |
| EP (1) | EP4402136A1 (es) |
| JP (2) | JP2024533482A (es) |
| KR (1) | KR20240056751A (es) |
| CN (1) | CN117940413A (es) |
| AR (1) | AR127055A1 (es) |
| AU (1) | AU2022348561B2 (es) |
| CA (1) | CA3231451A1 (es) |
| CL (2) | CL2024000683A1 (es) |
| CO (1) | CO2024003038A2 (es) |
| CR (1) | CR20240118A (es) |
| DO (1) | DOP2024000050A (es) |
| EC (1) | ECSP24020256A (es) |
| IL (1) | IL311251A (es) |
| MX (1) | MX2024003119A (es) |
| PE (1) | PE20240885A1 (es) |
| TW (3) | TWI822326B (es) |
| WO (1) | WO2023044326A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR127055A1 (es) * | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
| EP4676477A1 (en) * | 2023-03-10 | 2026-01-14 | Eli Lilly And Company | Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof |
| WO2025096300A1 (en) * | 2023-10-30 | 2025-05-08 | Eli Lilly And Company | Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives |
| WO2025193591A1 (en) | 2024-03-11 | 2025-09-18 | Eli Lilly And Company | Crystalline form of a tartrate salt of an sstr4 agonist |
| GB202408483D0 (en) | 2024-06-13 | 2024-07-31 | Maxion Therapeutics Ltd | Receptor agonists |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159941A (en) | 1996-05-14 | 2000-12-12 | Novo Nordisk A/S | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
| US6355613B1 (en) | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| US6063796A (en) | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
| US7834021B2 (en) | 2002-11-27 | 2010-11-16 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| US20100004339A1 (en) | 2003-10-06 | 2010-01-07 | Oy Juvantia Pharma Ltd. | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists |
| FI20031454A0 (fi) | 2003-10-06 | 2003-10-06 | Juvantia Pharma Ltd Oy | Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja |
| US7473787B2 (en) | 2003-10-14 | 2009-01-06 | Pfizer Inc | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| WO2007029086A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| WO2008075172A2 (en) | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN102395270B (zh) | 2008-07-07 | 2014-11-12 | 法斯根公司 | 化合物、含有其的药物组合物、其使用方法及其制备方法 |
| WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| JP2013542929A (ja) | 2010-09-28 | 2013-11-28 | パナセア バイオテック リミテッド | 新規ビシクロ環化合物 |
| EP2685828A4 (en) | 2011-03-17 | 2014-08-13 | Merck Sharp & Dohme | SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS |
| CN102675290B (zh) | 2011-03-18 | 2014-11-12 | 山东亨利医药科技有限责任公司 | 含有并环的二氢吡唑类化合物 |
| KR101556318B1 (ko) | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| JP6590927B2 (ja) | 2014-11-14 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）作動薬としてのアリール及びヘテロアリール縮合テトラヒドロ−１，４−オキサゼピンアミド |
| KR20170082632A (ko) | 2014-11-14 | 2017-07-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 소마토스타틴 수용체 아형 4 (sstr4) 작용제로서의 모르폴린 및 1,4-옥사제판 아미드 |
| WO2021233428A1 (zh) | 2020-05-21 | 2021-11-25 | 广州费米子科技有限责任公司 | 含氮饱和杂环化合物及其制备方法、药物组合物和应用 |
| KR20230015333A (ko) | 2020-05-21 | 2023-01-31 | 광저우 페르미온 테크놀로지 씨오., 엘티디. | 융합된 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물 및 용도 |
| WO2022012534A1 (zh) | 2020-07-13 | 2022-01-20 | 广州费米子科技有限责任公司 | 含氮杂环化合物、药物组合物和应用 |
| AR127055A1 (es) * | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
-
2022
- 2022-09-13 AR ARP220102484A patent/AR127055A1/es unknown
- 2022-09-13 TW TW111134517A patent/TWI822326B/zh active
- 2022-09-13 TW TW113126835A patent/TW202444703A/zh unknown
- 2022-09-13 TW TW112136333A patent/TWI860849B/zh active
- 2022-09-14 EP EP22783267.2A patent/EP4402136A1/en active Pending
- 2022-09-14 CA CA3231451A patent/CA3231451A1/en active Pending
- 2022-09-14 AU AU2022348561A patent/AU2022348561B2/en active Active
- 2022-09-14 IL IL311251A patent/IL311251A/en unknown
- 2022-09-14 US US17/944,429 patent/US11834435B2/en active Active
- 2022-09-14 MX MX2024003119A patent/MX2024003119A/es unknown
- 2022-09-14 JP JP2024516362A patent/JP2024533482A/ja active Pending
- 2022-09-14 KR KR1020247011858A patent/KR20240056751A/ko active Pending
- 2022-09-14 PE PE2024000415A patent/PE20240885A1/es unknown
- 2022-09-14 WO PCT/US2022/076401 patent/WO2023044326A1/en not_active Ceased
- 2022-09-14 CR CR20240118A patent/CR20240118A/es unknown
- 2022-09-14 CN CN202280062405.0A patent/CN117940413A/zh active Pending
-
2023
- 2023-08-07 US US18/366,218 patent/US12486249B2/en active Active
-
2024
- 2024-03-06 CL CL2024000683A patent/CL2024000683A1/es unknown
- 2024-03-13 CO CONC2024/0003038A patent/CO2024003038A2/es unknown
- 2024-03-14 EC ECSENADI202420256A patent/ECSP24020256A/es unknown
- 2024-03-14 DO DO2024000050A patent/DOP2024000050A/es unknown
-
2025
- 2025-04-23 JP JP2025071176A patent/JP2025111617A/ja active Pending
- 2025-07-22 CL CL2025002158A patent/CL2025002158A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR127055A1 (es) | 2023-12-13 |
| US20240067628A1 (en) | 2024-02-29 |
| CO2024003038A2 (es) | 2024-04-18 |
| US20230099116A1 (en) | 2023-03-30 |
| WO2023044326A1 (en) | 2023-03-23 |
| US11834435B2 (en) | 2023-12-05 |
| MX2024003119A (es) | 2024-04-09 |
| DOP2024000050A (es) | 2024-04-30 |
| TWI860849B (zh) | 2024-11-01 |
| TW202400577A (zh) | 2024-01-01 |
| EP4402136A1 (en) | 2024-07-24 |
| AU2022348561A1 (en) | 2024-03-14 |
| JP2025111617A (ja) | 2025-07-30 |
| CN117940413A (zh) | 2024-04-26 |
| JP2024533482A (ja) | 2024-09-12 |
| TW202330492A (zh) | 2023-08-01 |
| CA3231451A1 (en) | 2023-03-23 |
| ECSP24020256A (es) | 2024-04-30 |
| TW202444703A (zh) | 2024-11-16 |
| AU2022348561B2 (en) | 2025-05-22 |
| KR20240056751A (ko) | 2024-04-30 |
| CR20240118A (es) | 2024-04-25 |
| IL311251A (en) | 2024-05-01 |
| TWI822326B (zh) | 2023-11-11 |
| CL2025002158A1 (es) | 2025-11-07 |
| CL2024000683A1 (es) | 2024-08-23 |
| US12486249B2 (en) | 2025-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240885A1 (es) | Sales agonistas de sstr4 | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| UY29827A1 (es) | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones | |
| PE20070541A1 (es) | Compuestos y composiciones que comprenden isoindol-imidas | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| AR036604A1 (es) | Derivados de 4-pirimidona 3-sustituida | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| PE20220937A1 (es) | Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| CL2011001093A1 (es) | Compuestos derivados de 4-[2-(2-fluorofenoximetil)fenil]piperidina, inhibidores de la recaptacion de serotonina y norepinefrina; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar el dolor neuropatico, fibromialgia, trastorno depresivo y obesidad entre otras. | |
| UY29639A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos | |
| AR126052A1 (es) | Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| CU20200102A7 (es) | Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| DOP2021000100A (es) | COMPUESTOS TETRÁMEROS ClCLICOS COMO INHIBIDORES DE PROPROTElNA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9) PARA EL TRATAMIENTO DE TRASTORNOS METABÓLICOS. | |
| CL2024002500A1 (es) | Inhibidores de proteínas de unión a emopamilo y usos de estos | |
| GT199900083A (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica. | |
| GT200600397A (es) | Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales | |
| GEAP202516802A (en) | Protac chimeric compound, preparation method thereof and use thereof | |
| SA522441781B1 (ar) | Tlr4 مادة مساعدة ذات نشاط معضد لـ | |
| AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello | |
| PE20040176A1 (es) | Ambroxol para el tratamiento de dolores cronicos | |
| GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon |